WO2000037676A1 - Procede d'identification de sequence - Google Patents

Procede d'identification de sequence Download PDF

Info

Publication number
WO2000037676A1
WO2000037676A1 PCT/GB1999/004352 GB9904352W WO0037676A1 WO 2000037676 A1 WO2000037676 A1 WO 2000037676A1 GB 9904352 W GB9904352 W GB 9904352W WO 0037676 A1 WO0037676 A1 WO 0037676A1
Authority
WO
WIPO (PCT)
Prior art keywords
activity
synthesis
gene
essential protein
bacterial
Prior art date
Application number
PCT/GB1999/004352
Other languages
English (en)
Inventor
Jeffrey Errington
Original Assignee
Isis Innovation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation Limited filed Critical Isis Innovation Limited
Priority to JP2000589729A priority Critical patent/JP2002533095A/ja
Priority to EP99962397A priority patent/EP1141397A1/fr
Publication of WO2000037676A1 publication Critical patent/WO2000037676A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Definitions

  • Target identification Genes that appear to be essential for bacterial viability are first identified. Most often, this is based on inviability of the cells containing a form of the gene that has been inactivated. Information from genomic DNA sequence is used to identify genes that are conserved in bacteria but not in humans. The targeting of such genes is thought to be more likely to provide inhibitors that will be specific to bacterial cells - a crucial feature for efficacy as an antibiotic.
  • a suitable means of screening for inhibition of the function of the target gene is then devised. This can be either an in vitro, biochemical assay, or a whole cell assay.
  • the assay is configured in such a way that a very large number of chemical compounds can be screened for activity against the target function. Many pharmaceutical companies have access to very large collections of compounds that can be screened. Compounds detected in this way provide lead molecules from which antibodies can potentially be derived.
  • the present invention makes use of this feedback regulation, hereinafter sometimes called autoregulation, to provide whole cell assays for screening compounds for antibiotic or other biological activity. It may be convenient for this purpose to make use (to effect expression of a reporter gene) of a promoter for the target gene. Alternatively other regulatory sequences, e.g. promoters of other genes of known or unknown function, may be used for the purpose. It is another object of this invention to provide a means of identifying such regulatory sequences.
  • the invention provides a method for identifying a modulator of a bacterial essential protein comprising: i) providing a bacterial host cell which expresses the essential protein and having a polynucleotide construct comprising a regulatory sequence operably linked to a reporter gene wherein the regulatory sequence is associated with a feed back mechanism responsive to changes in the synthesis or activity of the essential protein; ii) contacting a test substance with the host cell; and iii) monitoring expression of the reporter gene to determine thereby whether the said substance modulates the synthesis or activity of the essential protein.
  • the invention provides an inhibitor of a bacterial essential protein identifiable by the method of the invention; an inhibitor of a bacterial essential protein identified according to the method of the invention; an inhibitor as defined above for use in a method of treatment of a human or animal body; or an inhibitor as defined above for use as an antibiotic.
  • the invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the inhibitor as defined above and a pharmaceutically acceptable carrier.
  • the invention provides a method for identifying a regulatory sequence which is affected by a feedback mechanism on alteration of synthesis or activity of a bacterial essential protein comprising: i) providing a bacterial cell having a reporter gene under the control of a candidate regulatory sequence; ii) selecting a target essential protein which is expressed in the organism; iii) altering the synthesis or activity of the essential protein; and iv) monitoring expression of the reporter gene. v) determining thereby whether the candidate regulatory sequence is affected by a feedback mechanism.
  • the invention also provides a method of identifying a regulatory sequence whose activity is affected by a feedback mechanism on alteration of the synthesis or activity of an essential bacterial protein comprising monitoring gene expression in the presence of normal and altered synthesis or activity of the essential protein, and identifying thereby a regulatory sequence whose activity is affected by a feedback mechanism associated with the essential bacterial protein.
  • the invention provides cells of an organism suitable for screening compounds for biological activity, which cells contain a chromosome including: a) a target gene whose expression or activity is subject to a feedback mechanism, and b) an artificially introduced reporter gene under the control of a regulatory sequence associated with the said feedback mechanism, whereby a reduction of synthesis or activity of a target gene expression product is associated with an increase in the expression of the reporter gene.
  • a method of screening compounds for biological activity which method comprises incubating the compounds with aliquots of the cells as defined, and observing the level of expression of the reporter gene.
  • the invention provides compounds e.g. antibiotics identified by the method; and use of the compounds so identified to treat, e.g. kill or inhibit the growth of, bacteria.
  • the invention provides a method for screening for an inhibitor or modulator of a bacterial essential protein.
  • the essential protein is encoded by a target gene and may be of known or unknown function. Alteration of expression or activity of the target essential protein leads to a feedback mechanism in the bacteria, which serves to alter or up regulate expression from a promoter or regulatory sequence of a bacterial gene.
  • the nature of the feedback mechanism is not critical; it may operate at the RNA level or at the protein level and may involve transcription and/or translation of the target gene and/or activity of a target gene expression product.
  • the target gene will generally encode a protein that is essential for viability and well conserved in bacteria or other micro-organisms but absent from or highly dissimilar in higher organisms e.g. mammals or humans.
  • a feedback mechanism may operate in the bacterial cell to compensate for the alteration.
  • the feedback mechanism may operate on a regulatory sequence e.g. a promoter of the target gene.
  • a reduction of synthesis or activity of a target gene expression product may be associated, via the feedback mechanism, with an increase in activity of the promoter of the target gene.
  • a polynucleotide construct is provided in the bacterial cell comprising a reporter gene under the control of the promoter of the target gene.
  • a reduction in the synthesis or activity of the essential protein may be associated with an alteration, and generally an increase in the expression of another bacterial gene, for example, through up regulation of the promoter for that gene.
  • a polynucleotide construct comprising a reporter gene under the control of the promoter or other regulatory sequence that is not associated with the target essential protein per se but is subject to upregulation through a feed back mechanism when the activity or synthesis of the essential protein is altered.
  • the invention also provides methods of identifying potential genes which are subject to a feed back mechanism effected by alterations in the activity or synthesis of the essential functional protein under investigation. Once such a gene has been identified, a reporter gene under the control of the promoter or regulatory sequence for that gene may be readily constructed and incorporated in a bacterial cell for use in accordance with an assay of the invention.
  • the cells of the invention thus contain an artificially introduced reporter gene under the control of a regulatory sequence associated with the target gene that is to say affected by a feedback mechanism associated with a reduction in the synthesis or activity of the target gene product.
  • the reporter gene comprises the gene whose expression is altered by the feedback mechanism described above and the assay comprises monitoring for up regulation for that gene, for example using a gene array or proteomics technique to monitor transcription or expression of the gene.
  • the target gene in accordance with the present invention encodes a protein which is essential for bacterial viability such that a test substance which effects the essential protein, either effecting its synthesis or activity may be useful as an antibiotic.
  • a target gene must also in some way be associated with a feedback mechanism effecting either the expression of the target gene itself or other genes within the bacterial cell.
  • the promoters or other regulatory sequences of the target gene or genes affected by the feedback mechanism may thus be useful when coupled to a reporter gene in an assay. By monitoring for expression of the reporter gene, a substance which inhibit synthesis or activity of the target protein may be identified.
  • Proteins involved in cell wall precursor synthesis, teichoic acid synthesis, DNA replication, RNA synthesis, cell division, chromosome segregation, translation and other essential genes are all suitable targets for use in accordance with the invention. Some specific examples are discussed in more detail below, by way of example only. The following are envisaged as preferred target genes for use in B. subtilis or other bacteria. These may include proteins involved in the following process:
  • Cell wall (peptidoglycan) precursor synthesis including the products of the genes: murA.B.C,D,E,F,G,Z. dal. dap. ddlA);
  • Teichoic acid synthesis (tagA.B.C,D,E,F,G,H, gtaB); DNA replication (dnaA, gyrA,B. topA.B, ligfyerGJ):
  • RNA synthesis (sigA, rpoA, rpoB, rpoC);
  • DnaA - an example of a DNA replication protein
  • the dnaA gene is widely conserved among bacterial species and in E.coli and B. subtilis at least, it is essential, being required for initiation of DNA replication (although the Cyanobacterial gene was recently reported to be non-essential; Richter et al, 1998, J. Bacteriol. 180, 4946-4949). Eukaryotes. in contrast, use a quite different mechanism to initiate chromosome replication, so agents that specifically inhibit DnaA function should have selective toxicity against bacteria. Accumulation of DnaA during the cell cycle is thought to result in gradual filling of binding sites ("DnaA boxes") in the oriC region. Eventually, enough DnaA accumulates to allow formation of an initiation complex that leads to the initiation of bidirectional chromosome replication.
  • DnaA boxes binding sites
  • the dnaA gene is monocistronic and located right next to oriC (Moriya et al., 1988, EMBO J. 7, 2911-2917). There is a long upstream regulatory region containing several DnaA boxes. Two of these appear to overlap the promoter region of the gene. There is well-documented evidence in both E.coli and B. subtilis that DnaA negatively autoregulates, so depletion of DnaA is compensated for by increased transcription from its promoter. Preliminary experiments are in progress to show that depletion of DnaA protein (by artificially repressing its gene) result in increased transcription from the dnaA promoter.
  • reporter genes coupled to the dnaA promoter should provide a convenient means of screening for inhibitors of this excellent antibiotic target.
  • Promoters to genes uninvolved with DNA replication e.g. the P M/ promoter, induced by the presence of xylose
  • the promoters of such genes might provide better control promoters to ensure the specificity of inhibitors against DnaA, rather against DNA replication in general.
  • a dual reporter system based on the ? ⁇ m4 and possibly P X ⁇ promoters should provide a sensitive and specific whole cell assay for inhibitors of DnaA function.
  • PG peptidoglycan
  • a wall is present in virtually all eubacteria. It is composed of long glycan (amino sugar) polymers crosslinked by short peptides. The peptides are unusual in that they contain amino acids in the D-isomeric state. There is no structure equivalent to the cell wall in higher eukaryotes and D-amino acids are generally absent. Many important antibiotics, including penicillins, cephalosporins and vancomycin act on PG synthesis.
  • D-alanine which is universally found in PG, is obtained by bacteria either from their growth medium or by the action of an enzyme, D-alanine racemase, encoded by the dal gene, which converts L-alanine to the D- form.
  • dal is a very highly conserved gene in eubacteria but absent from eukaryotes. Tests are in progress to determine whether the dal promoter is autoregulated; its promoter is expected to be up-regulated in response to depletion of the Dal protein. If this is the case, the promoter can be used to screen for inhibitors of Dal. P xy ⁇ can again be used as a control, although there might be better promoters (e.g. one responding negatively to increases in the substrate used by Dal).
  • InfC - an example of a protein involved in translation
  • initiation codons are defined by a "ribosome- binding site" (RBS), which lies close to the initiation codon. which is usually AUG but sometimes UUG or GUG.
  • RBS ribosome- binding site
  • the first AUG in the mRNA tends to be used, irrespective of the context - there is no equivalent of the RBS.
  • Translation initiation factor 3 of bacteria is highly conserved in bacteria and seems to be required for specificity of initiation at start codons. In both B. subtilis and E.coli, the initiator codon of the infC gene is highly unusual - AUU.
  • Both will carry a promoter driving transcription of the infC translation initiation region; in one case, the reporter gene will be fused in frame with the beginning of the infC coding region, including the AUU initiation codon; the other will have a different reporter gene fused to an identical leader except with AUG as initiator.
  • the first reporter should induce when InfC is depleted or inhibited. The latter will provide a control essentially unresponsive to changes in the levels of InfC.
  • Fmt - an example of a protein involved in the translation
  • Methionyl-tRNA formyltransferase carries out the final step in synthesis of the initiator tRNA in bacteria.
  • Bacterial cells use a special initiator tRNA, tRNA Fmt , specifically at start codons.
  • Eukaryotic cells use the normal tRNA for methionine at both initiator and internal codons and so have no need of Fmt.
  • Disruption of the fmt gene of E.coli causes a severe growth defect (Guillon, J.-M., Mechulam, Y., Schmitter, J.-M., Blanquet, S., Fayat, G. (1992) J.
  • a second polynucleotide construct is provided in the bacterial host cell comprising a second reporter gene linked to a second promoter.
  • the second promoter is provided such that under the conditions of the assay, in the absence of a test substance the second reporter gene would normally be expected to be expressed. This allows for non specific effects of the test substance to be identified. For example, if the test substance is a general inhibitor of translation within the bacterial cell, no expression of the second reporter gene would be expected.
  • the first and/or second reporter genes encode products which can readily be detected.
  • the reporter product may be detected by fluorescent, luminescent or other standard reporting techniques.
  • the reporter gene products may comprise an enzyme such as ⁇ -galactosidase. production of which may be identified by use of colorogenic or fluorogenic enzymes substrates.
  • Other reporter genes include ⁇ -glucuronidase, green fluorescent protein (GFP) and variants thereof, luciferase. chloramphenicol acetyl transferase. catechol oxidase, an antigen which may readily be recognised by an antibody, other affinity ligands such as streptavadin/biotin or protein A which may be detected by antibodies etc.
  • the first and second reporter genes where present are selected such that it is possible to differentiate between expression of the first reporter gene and expression of the second reporter gene.
  • no second reporter gene is provided.
  • other properties such as the optical density of the bacterial culture may be monitored with a view to assessing to what extent non-specific effects are occurring based on changes in culture growth which may be taken into account when assessing the effect of the test substance.
  • the polynucleotide construct(s) comprise a promoter operably linked to the reporter gene to be expressed.
  • the second promoter comprises an inducible promoter. The conditions required to induce this promoter can be applied to the host cell when adding the test substance during the course of the assay.
  • inducers include xylose, tetracycline, lactose and derivatives thereof including IPTG, arabinose and gluconate or a change of temperature.
  • inducers include xylose, tetracycline, lactose and derivatives thereof including IPTG, arabinose and gluconate or a change of temperature.
  • the promoter can be induced by increased temperatures.
  • the regulatory sequence or promoters associated with the feedback mechanism may comprise an endogenous bacterial promoter, or a polynucleotide homologous to such an endogenous promoter which retains the activity of the promoter i.e. is affected by the feedback mechanism.
  • a non-naturally occurring promoter may be provided comprising responsive elements which respond to the feedback mechanism coupled to other regulatory sequences sufficient to operably express the reporter gene via the feedback mechanism.
  • operably linked refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.
  • a regulatory sequence such as a promoter
  • operably linked to a coding sequence is positioned in such a way that expression of the coding sequence is achieved under conditions compatible with the regulatory sequence.
  • the polynucleotide construct(s) may be provided as vector(s) for transformation of the bacterial host cell.
  • the polynucleotide constructs may be provided on the same or different vectors.
  • Vectors may be used to replicate the vectors in a compatible host cell.
  • the vectors may be for example plasmid vectors provided with an origin of replication and optionally a regulator of the promoter.
  • the vectors may contain one or more selectable marker genes such as ampicillin or chloramphenicol resistance genes for selection in bacterial cells.
  • the invention also relates to a host cell transformed, conjugated or transduced with first and second polynucleotide constructs for the expression of the first and second reporter genes.
  • the assay of the invention is used to screen for compounds which modulate synthesis or activity of the bacterial essential protein. Any suitable format may be used for the assay for identifying a modulator of bacterial protein activity (the target protein).
  • the way in which the assay is carried out will depend in part of the nature of the first and where present second reporter genes. In some instances it may be necessary to divide a sample containing the host cells following administration of the test substance in order to monitor separately for first and second reporter gene activity.
  • the host cells are preferably bacterial cells and may be selected from Bacillus subtilis, E coli, Salmonella, Streptococcus, Staphylococcus etc.
  • the conditions of the assay are selected such that the host bacterial cell may grow in the absence of the test substance.
  • the assay is carried out under conditions which allow for the feedback mechanism to operate if there is an alteration of the synthesis or activity of the target protein such that the reporter gene is expressed. Additional control experiments may be appropriate. The progress of the assay can be followed in the presence and in the absence of the test substance. Known target protein modulators, may be used as positive controls in order to show a comparable or similar effect in a test substance. Known antibiotics may be tested to demonstrate their effect on the target protein. Additional assays may be carried out for example on mammalian cells or in a mammalian host to check that the test substance does not show adverse side effect on such host cells.
  • test substances which can be tested in the above assays include combinatorial libraries, defined chemical entities, peptide and peptide mimetics, oligonucleotides and natural product libraries, such as display (e.g. phage display libraries) and antibody products.
  • Test substances may be used in an initial screen of, for example, ten substances per reaction, and the substance of these batches which show inhibition or activation tested individually.
  • Test substances may be used at concentrations from l ⁇ M to lOmM, preferably from l ⁇ M to lOO ⁇ M, more preferably from l ⁇ M to lO ⁇ M.
  • Complex mixtures of natural origin e.g. filtrates from bacterial cultures, or plant extracts
  • Inhibitors of target bacterial protein activity may be used to restrict the growth of bacteria.
  • Such inhibitors may be used to treat bacterial conditions in humans or animals and thus may be used as antibiotics to treat such bacterial infection.
  • Such inhibitors may be administered in a variety of dosage forms.
  • inhibitors can be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.
  • the inhibitors may also be administered parenterally, either subcutaneously, intravenously, intramuscularly, intrasternally. transdermally or by infusion techniques.
  • the modulators may also be administered as suppositories. A physician will be able to determine the required route of administration for each particular patient.
  • a modulator for use in prophylaxis or treatment will depend upon factors such as the nature of the exact modulator, whether a pharmaceutical or veterinary use is intended, etc.
  • a modulator may be formulated for simultaneous, separate or sequential use.
  • a modulator of target protein activity is typically formulated for administration in the present invention with a pharmaceutically acceptable carrier or diluent.
  • the pharmaceutical carrier or diluent may be, for example, an isotonic solution.
  • solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents; e.g.
  • Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
  • the syrups may contain as carriers, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
  • Suspensions and emulsions may contain as carrier, for example a natural gum. agar. sodium alginate. pectin, methylcellulose. carboxymethylcellulose. or polyvinyl alcohol.
  • the suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier. e.g. sterile water, olive oil, ethyl oleate. glycols. e.g. propylene glycol. and if desired, a suitable amount of lidocaine hydrochloride.
  • Solutions for intravenous or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
  • a therapeutically effective amount of a modulator is administered to a patient.
  • the dose of modulator may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. Again, a physician will be able to determine the required route of administration and dosage for any particular patient.
  • a typical daily dose is from about 0.1 to 50 mg per kg, preferably from about O.lmg/kg to lOmg/kg of body weight, according to the activity of the specific inhibitor, the age, weight and conditions of the subject to be treated, the type and severity of the infection and the frequency and route of administration.
  • daily dosage levels are from 5 mg to 2 g.
  • a high throughput screen runs in the following way.
  • a strain of B. subtilis is constructed containing two reporter genes encoding enzymes or proteins that can be detected, such as ⁇ -galactosidase and ⁇ -glucuronidase.
  • Reporter genes capable of being expressed in Bacillus species are well known and documented in the literature. Reporter genes are preferably chosen so that their products can be readily assayed simultaneously.
  • Green fluorescent protein has the advantage that its intrinsic fluorescence allows the protein to be assayed by direct fluorimetric measurement. LacZ has been used for more than 10 years with great success in B. subtilis and there is a range of useful substrates that generate coloured or fluorescent products upon hydrolysis by ⁇ -galactosidase.
  • the uidA gene of E.coli has recently been harnessed for similar purposes, and the range of substrates available for the gene product, ⁇ - glucuronidase is similar to that for ⁇ -galactosidase.
  • Two different fluorogenic substrates may be used to assay the activities of the two reporters simultaneously in a single reaction.
  • One reporter is fused to a sequence that causes increased expression in the absence of the desired function (e.g. gyrase); the other to a sequence that gives unchanged or decreased expression.
  • the dual reporter strain is grown in an appropriate medium, dispensed into a vessel allowing large scale screening, such as the wells of microtitre plates. Each well would contain at least one test compound.
  • the cells would be incubated for an appropriate time period (preferably two or more cell doublings), after which (if necessary, depending on the reporters used) a reaction cocktail allowing simultaneous assay of the two reporter enzymes would be added.
  • the assays might be based on enzyme substrates giving e.g. chemiluminescent or fluorescent or coloured products.
  • chemiluminescent or fluorescent or coloured products For fluorogenic substrates the presence of either or both enzymes may be detected simultaneously by a fluorimeter set to receive two different appropriate wavelengths.
  • a positive response in terms of inhibition of DNA gyrase, would be indicated by increased activity of ⁇ -galactosidase and decreased ⁇ -glucuronidase. Compounds eliciting such a response would be potential antimicrobial agents with DNA gyrase as the likely target.
  • the chemicals could be individually spotted onto a lawn of cell plated on a growth medium containing colorigenic or fluorogenic substrates. Chemicals eliciting an appropriate response would be detectable by their enhancement or inhibition of enzyme activity in the vicinity of the spot.
  • the present invention also relates to the use of regulatory sequences or promoters which are not necessarily the promoter of the target gene itself but a promoter which is up-regulated in response to a decrease in the synthesis or activity of the target gene.
  • the invention also provides a method for identifying such a regulatory sequence by looking for differential expression of a gene under the control of a regulatory sequence when the synthesis or activity of an essential protein is altered.
  • an assay of the invention may involve monitoring differential expression of the gene affected by the feedback mechanism.
  • Identification of differential expression of a gene under control of the regulatory sequence may be carried out in a number of different ways.
  • a library is prepared comprising fragments of the chromosome of a bacterial gene, each fused to a reporter gene. Such constructs are used to transform bacteria. The synthesis or activity of the essential target gene is then altered and expression of the reporter gene is monitored. Those constructs which show upregulation of the reporter gene are then further analysed to identify those regulatory sequences which are upregulated in response to an alteration of the synthesis or activity of the essential target gene.
  • differential expression maybe monitored using a gene array of nucleotide sequences from the genes of the organism and analysing which genes are upregulated in response to alterations in the synthesis or activity of the target protein.
  • differential expression could be analysed by recovering proteins from the organism and separating the recovered proteins to observe changes resulting from alterations in the synthesis or activity of the target gene.
  • Promoter or regulatory sequences associated with such genes or proteins whose expression is altered in response to alterations in the synthesis or activity of the essential target gene may then be used in accordance with an assay of the invention.
  • a gene whose expression if affected by alternations in the expression or activity of the target essential protein is selected.
  • Bacterial cells are incubated in the presence and absence of a test substance and differential expression of the gene is investigated by one of the methods outlined above.
  • the invention also provides a method of identifying a regulatory sequence, which method comprises the steps of:- i) selecting a target gene in a chromosome of an organism wherein expression of the target gene is subject to a feedback mechanism, ii) altering the synthesis or activity of an expression product of the target gene, and iii) observing a corresponding change in activity of a regulatory sequence associated with the said feedback mechanism, wherein there is introduced into the chromosome of the organism a reporter gene under the control of the regulatory sequence, and step iii) is performed by observing a corresponding change in the expression of the reporter gene.
  • Step ii) of that method preferably involves controlling the expression of the target gene through the use of a genetic construct containing a known repressor or promoter sequence so as to modulate a level of an expression product via exposure of the cells to an external chemical or physical inducing factor; or isolating a conditional mutation in the gene, which allows activity of its product only under certain conditions, such as low or high temperature.
  • step iii) is performed by observing a corresponding change in the expression of the reporter gene.
  • a library of constructs of potential regulatory sequences associated with the said feedback mechanism each potential regulatory sequence fused to a reporter gene.
  • iii) is performed by genetically modifying aliquots of cells of the organism by introducing into the chromosome of the cells of each aliquot a different construct of the library.
  • the genetic modification may simply comprise introduction of a plasmid containing a construct.
  • the potential regulatory sequences are preferably DNA fragments of approximately 50-1000 bp of the genome of the organism.
  • a library would preferably contain at least 10 different constructs.
  • the DNA fragments of the library comprise the entire genome of the organism.
  • Another method involves providing an array of DNA sequences of genes of the organism and monitoring for differential mRNA expression in the presence of functional inhibition of the target gene.
  • the array is of DNA sequences taken from each of the genes of the organism and provided in spots at spaced locations on a surface of a support. Cells of the organism are incubated under conditions which permit expression of the target gene, RNA is recovered and if desired converted to cDNA. Either the RNA or the cDNA is applied to the array under hybridisation conditions, and a hybridisation pattern is noted. Another aliquot of cells of the organism is incubated under conditions to alter or prevent expression of the target gene.
  • RNA is recovered and RNA or cDNA is applied to the array under hybridisation conditions in order to generate a hybridisation pattern different from the previous one.
  • the differences are noted and are indicative of genes and their regulatory sequences which are involved in a feedback mechanism associated with the target gene.
  • Such gene expression arrays have been described in the literature and used to investigate feedback mechanisms of micro-organisms, but not, it is believed, for the purpose of identifying regulatory sequences for use in screening for antibiotics. (DeRisi, J L et al, 1997).
  • step iii) is performed by recovering proteins from cells of the organism, separating the recovered proteins and observing a corresponding change in concentration of at least one individual protein.
  • a first aliquot of cells of the organism is cultured under conditions to permit expression of the target gene. Proteins in the cell are recovered and separated e.g. by use of a two dimensional electrophoresis gel. This technique is well known in the literature (Anderson, N L et al. 1998) and gives rise to a pattern where the identity of each protein is known or can be determined. Then another aliquot of the cells is incubated under conditions to prevent expression of the target gene. Recovered proteins are separated by electrophoresis to produce a pattern different from the first.
  • the differences are observed and are indicative of genes and regulatory sequences that are involved in a feedback mechanism associated with the target gene.
  • the first of these three methods involves a substantial capital investment to create a library of constructs of potential regulatory sequences each fused to a reporter gene: but it should be effective to identify any or all regulatory sequences involved in the feedback mechanism associated with the target gene.
  • the second method using gene expression arrays avoids the expense of creation of a library, and should be effective to pick up regulatory sequences involved in feedback mechanisms where transcription is altered.
  • the third method, using "proteomics" is relatively simple and cheap, but may not be effective to pick up regulatory sequences where the feed back mechanism involves mRNA synthesis or protein stability or activity.
  • the organism is preferably a bacterium e.g. Bacillus subtilis, although other prokaryotes and even simple eukaryotes such as yeasts are envisaged. It may be convenient to use an organism whose genome is sufficiently small that it can be chopped up into random fragments of convenient size which constitute a library of potential regulatory sequences, with the number of potential regulatory sequences of the library not being impractically large. This is a property possessed by bacteria and possibly also by yeasts.
  • a large (> 10,000) random collection of short (approximately 50 to 1,000 bp) DNA sequences from the chromosome of B. subtilis or a related organism are fused to an appropriate reporter gene (e.g. lacZ). Methods known in the art are available to achieve this (reviewed by Errington. 1990). Each member of the collection of fusions is then introduced into a cell of a strain of B. subtilis that had been genetically engineered to allow depletion of the target function.
  • a regulatory sequence exhibiting the desirable property of modulating reporter gene expression upon depletion of the target function would provide a means of screening for compounds which are specific modulators of the target gene function.
  • the resultant change in DNA supercoiling in the cell should result in increased expression from the promoter of the gyrA gene.
  • Some random fragments of DNA e.g. one containing the gyrA promoter itself
  • Isolating the gyrA promoter fragment (or some similarly behaving regulatory sequence), and fusing it to a reporter gene gives a genetic construct that would respond, with increased expression, to inhibition of DNA gyrase by chemical inhibitors (i.e.
  • any operational screen it is preferable to include a second reporter gene, encoding a non-gyrase-dependent promoter fragment, to control for non-specific inhibitors of gene expression.
  • growth of the culture could be followed by, for example measurement of optical density and correction made for non-specific effects on culture growth.
  • a reporter would provide a control reporter that would most likely increase the specifity of the assay for inhibitors of DNA gyrase.
  • yeast genetics should be facile enough to allow it to be used. This opens up the possibility of identifying compounds that inhibit specific eukaryotic functions; at least those that are conserved in yeast.
  • the yeast strain may first have its endogenous gene replaced with the equivalent human gene to make the screen more direct and specific.
  • GyrA is one subunit of the essential DNA gyrase protein, so that in the absence of IPTG, the culture growth was strongly impaired Fig 1 A. Integration of plasmid pATl also places a lacZ reporter gene under the control of the natural promoter for gyrA. The level of expression of this reporter was increased in the absence of IPTG, compared with the control culture in which IPTG remains present (Fig.1 B) indicating that the promoter is subject to negative feedback regulation. Reduction in the availability of GyrA protein results in an increase in transcription from the gyrA promoter.
  • strains 2842 and 2844 provide a means of detecting inhibitors of DNA gyrase, since treatment of the cells with such compounds should similarly elicit increased relative expression of the lacZ reporter gene.
  • strain 2844 was grown in the presence of IPTG and treated with a range of concentrations of a known inhibitor of DNA gyrase, nalidixic acid. As shown in Fig. 2, at a range of concentrations of nalidixic acid, from 2 ⁇ g/ml through 16 ⁇ g/ml, the specific activity of ⁇ -galactosidase (encoded by the gyrA-lacZ reporter gene) was increased to about 3-fold greater than that of the untreated cells.
  • samples from a culture of strain 2844 were introduced into the wells of a 96-well microtire plate to which a series of antibiotics with a range of known modes of action had been added. Each antibiotic was added in the form of a 2-fold dilution series. After allowing 2 h for growth, the ⁇ -galactosidase specific activity was measured, using culture optical density (OD 600 ) to correct for reductions in cell growth due to the antibiotic action.
  • Figures 3A, B and C plot the activity against the well number.
  • the concentration of antibiotic in well 1 is as follows in ⁇ g/ml Fig 3A: polymyxin: 256, proflavin 165, trimethoprim 128, vancomycin 8, nalidixic acid 128; Fig 3B: ampicillin 128, carbenicillin 1024, chloramphenicol 128, nalidixic acid 128. rifampicin 64; Fig 3C: bacitracin 1024, chlorhexadine 128, monensin 128, novobiocin 128, phosphomycin 750. Wells 2-12 then follow the 2-fold dilution series. As shown in Fig.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des cellules de Bacillus subtilis ou d'autres microorganismes qui conviennent pour la sélection de composants qui présentent une activité antibiotique. Ces cellules expriment une protéine essentielle et comprennent un polynucléotide de synthèse présentant une séquence régulatrice associée de manière fonctionnelle à un gène rapporteur. Cette séquence régulatrice est associée à un mécanisme de rétroaction réagissant à une modification de la synthèse ou de l'activité de la protéine essentielle. L'invention concerne également un procédé permettant de sélectionner des composés présentant une activité antibiotique ou une autre activité biologique. Ce procédé consiste à incuber les composés avec des portions aliquotes des cellules décrites, et à observer les niveaux d'expression du gène rapporteur. L'invention concerne également de procédés permettant d'identifier des séquences régulatrices adéquates qui ne sont pas des promoteurs du gène cible.
PCT/GB1999/004352 1998-12-22 1999-12-22 Procede d'identification de sequence WO2000037676A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2000589729A JP2002533095A (ja) 1998-12-22 1999-12-22 配列の同定方法
EP99962397A EP1141397A1 (fr) 1998-12-22 1999-12-22 Procede d'identification de sequence

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98310567 1998-12-22
EP98310567.7 1998-12-22

Publications (1)

Publication Number Publication Date
WO2000037676A1 true WO2000037676A1 (fr) 2000-06-29

Family

ID=8235222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1999/004352 WO2000037676A1 (fr) 1998-12-22 1999-12-22 Procede d'identification de sequence

Country Status (3)

Country Link
EP (1) EP1141397A1 (fr)
JP (1) JP2002533095A (fr)
WO (1) WO2000037676A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087963A1 (fr) * 2003-03-31 2004-10-14 Astrazeneca Ab Dosage biologique modulateur de la topoisomerase

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012887A1 (fr) * 1989-04-20 1990-11-01 Bio-Orbit Oy Determination des facteurs affectant la regulation et/ou la replication de genes
ZA942779B (en) * 1993-04-22 1995-01-09 American Cyanamid Co DNA gyrase inhibitor assay
WO1995019446A1 (fr) * 1994-01-17 1995-07-20 Marko Virta Procede pour determiner la presence d'un metal dans un echantillon
WO1997005241A2 (fr) * 1995-07-26 1997-02-13 Creative Biomolecules, Inc. Procedes et compositions d'identification d'analogues de morphogenes
EP0837142A1 (fr) * 1996-10-15 1998-04-22 Smithkline Beecham Corporation Procédé de détermination de gènes essentiels dans des agents pathogènes
WO1998035054A1 (fr) * 1997-02-10 1998-08-13 Ribogene, Inc. Procedes destines au criblage d'antibiotiques
WO1999064567A1 (fr) * 1998-06-05 1999-12-16 Discovery Technologies Ltd. Lignees cellulaires transformees, exprimant des recepteurs heterologues lies a la proteine g

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012887A1 (fr) * 1989-04-20 1990-11-01 Bio-Orbit Oy Determination des facteurs affectant la regulation et/ou la replication de genes
ZA942779B (en) * 1993-04-22 1995-01-09 American Cyanamid Co DNA gyrase inhibitor assay
WO1995019446A1 (fr) * 1994-01-17 1995-07-20 Marko Virta Procede pour determiner la presence d'un metal dans un echantillon
WO1997005241A2 (fr) * 1995-07-26 1997-02-13 Creative Biomolecules, Inc. Procedes et compositions d'identification d'analogues de morphogenes
EP0837142A1 (fr) * 1996-10-15 1998-04-22 Smithkline Beecham Corporation Procédé de détermination de gènes essentiels dans des agents pathogènes
WO1998035054A1 (fr) * 1997-02-10 1998-08-13 Ribogene, Inc. Procedes destines au criblage d'antibiotiques
WO1999064567A1 (fr) * 1998-06-05 1999-12-16 Discovery Technologies Ltd. Lignees cellulaires transformees, exprimant des recepteurs heterologues lies a la proteine g

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; NEUMANN S ET AL: "Discoordinate gene expression of gyrA and gyrB in response to DNA gyrase inhibition in Escherichia coli.", XP002106690 *
DATABASE WPI Week 199522, Derwent World Patents Index; AN 170454, XP002138099 *
DERISI J L ET AL: "EXPLORING THE METABOLIC AND GENETIC CONTROL OF GENE EXPRESSION ON A GENOMIC SCALE", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 278, 24 October 1997 (1997-10-24), pages 680 - 686, XP000700250, ISSN: 0036-8075 *
JACOBS W R ET AL: "RAPID ASSESSMENT OF DRUG SUSCEPTIBILITIES OF MYCOBACTERIUM TUBERCULOSIS BY MEANS OF LUCIFERASE REPORTER PHAGES", SCIENCE,US,AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, vol. 260, no. 5109, 7 May 1993 (1993-05-07), pages 819 - 822, XP000673145, ISSN: 0036-8075 *
JOURNAL OF BASIC MICROBIOLOGY, (1997) 37 (1) 53-69. JOURNAL CODE: JOT. ISSN: 0233-111X., GERMANY: Germany, Federal Republic of *
KALABAT D Y ET AL: "Chitobiase, a new reporter enzyme.", BIOTECHNIQUES, (1998 DEC) 25 (6) 1030-5. JOURNAL CODE: AN3. ISSN: 0736-6205., United States, XP002106689 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087963A1 (fr) * 2003-03-31 2004-10-14 Astrazeneca Ab Dosage biologique modulateur de la topoisomerase

Also Published As

Publication number Publication date
EP1141397A1 (fr) 2001-10-10
JP2002533095A (ja) 2002-10-08

Similar Documents

Publication Publication Date Title
Ogura et al. Binding of response regulator DegU to the aprE promoter is inhibited by RapG, which is counteracted by extracellular PhrG in Bacillus subtilis
Bisicchia et al. The essential YycFG two‐component system controls cell wall metabolism in Bacillus subtilis
Ferrières et al. The RcsC sensor kinase is required for normal biofilm formation in Escherichia coli K‐12 and controls the expression of a regulon in response to growth on a solid surface
Zellars et al. Antiterminator‐dependent modulation of transcription elongation rates by NusB and NusG
Chalissery et al. Transcription termination defective mutants of Rho: role of different functions of Rho in releasing RNA from the elongation complex
KR20020089462A (ko) 변경된 유전자 발현의 확인을 위한 세포 어레이
Baptista et al. Single‐cell analysis of glycopeptide resistance gene expression in teicoplanin‐resistant mutants of a VanB‐type Enterococcus faecalis
WO2000005410A2 (fr) Procede de detection d'interactions proteine-proteine et kit d'utilisation
Carlson et al. Signal sequence processing is required for the assembly of LamB trimers in the outer membrane of Escherichia coli
EP0830457A1 (fr) Procedes d'evaluation de cibles antimicrobiennes
US20030108872A1 (en) Genomics-assisted rapid identification of targets
US5998159A (en) Methods for screening for antibiotics
WO1999035494A1 (fr) Methodes pour identifier des combinaisons de cibles et de dosages valides
US6846625B1 (en) Method for identifying validated target and assay combination for drug development
WO2000037676A1 (fr) Procede d'identification de sequence
Das et al. Molecular characterization of Vibrio cholerae Δ relA Δ spoT double mutants
JP2004533261A (ja) タンパク質の折りたたみを監視および調節することにより細菌におけるタンパク質の発現を改善する方法
WO2007040654A2 (fr) Procedes d'identification de composes antimicrobiens qui interrompent la biogenese des ribosomes
US20030003449A1 (en) Methods and compositions for the determination of protein function and identification of modulators thereof
JP4414000B2 (ja) バチルス株および抗生物質スクリーニング法
KR20030081342A (ko) 전사 조절인자를 규명하는 방법
Paiva et al. Effects of F‐encoded components and F‐pilin domains on the synthesis and membrane insertion of TraA'‐'PhoA fusion proteins
Peterson et al. Characterization of conserved bases in 4.5 S RNA of Escherichia coli by construction of new F′ factors
US20060078952A1 (en) Method for identifying antimicrobial molecules which interfere with apolipoprotein N-acyltransferase activity
Pogliano Genetic studies on the localization and regulation of Escherichia coli cell envelope proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 589729

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999962397

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999962397

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09869179

Country of ref document: US